Javara and Tryon Medical Partners have announced that they have formed a collaboration to offer industry-sponsored, outpatient clinical trials to Tryon Medical Partners’ patients.
“This partnership is a win-win for both our patients and doctors,” said Dr. Dale Owen, CEO of Tryon Medical Partners and a cardiologist with the practice. “Our patients will now have an opportunity to directly participate in advanced medical trials at no cost, and our doctors will be able to work closely with Javara’s medical professionals on the development of an array of innovative new drugs and interventions. It is also another significant milestone in Tryon’s rapid growth and development since we opened our first of eight clinics in the Charlotte region last September,” Owen added.
Javara’s Clinical Trial Navigators will be embedded within Tryon’s clinics in South Park and Uptown and work alongside Tryon’s doctors and medical staff. Javara and Tryon will initially conduct clinical trials in internal medicine, endocrinology and dermatology. The team expects initial trials to begin in September 2019, and to grow to have 35 to 45 clinical trials underway within the first 18 months.
“Javara is very pleased to be partnering with the Tryon Medical Partners team to incorporate clinical research into their care offerings to patients and we are eager to get started,” said Jennifer Byrne, CEO of Javara. “We have watched Dr. Owen and his fellow doctors with great interest since they formed an independent practice last year, and believe we have found the perfect partner to work with in the Charlotte region to better integrate clinical research as part of care options for patients.”
The trials are part of the testing required by the Federal Drug Administration before new drugs or devices are approved for broad use with patients.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.